PeptideStack
5.2kquestions
20kanswers
220users

clinical-trials

Page 7 of 32 · 745 questions tagged clinical-trials.

745 questions · sorted by votes · page 7 of 32

29 votes5 answers26k views
What does SURMOUNT-1 actually establish about tirzepatide?

Setup, so nobody has to ask: SURMOUNT-1 · tirzepatide. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
cardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

68 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
asked by charge_state_3 16k · 2.2 years ago
29 votes 5 answers24k views
What does SELECT report at the 2 mg dose level?

The specifics, since they change the answer: SELECT · 2 mg. I want to understand what this actually establishes, as opposed to what it is being used to imply. My…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by halvard_ness 69k · 8 months ago
29 votes 5 answers23k views
What is the reported incidence of dizziness on semaglutide in SELECT?

What I am working with: dizziness · semaglutide · SELECT. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

472 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by assay_blank 45k · 9 months ago
29 votes 1 answer20k views
How comparable are liraglutide and cagrilintide on the evidence available?

What I am working with: liraglutide · cagrilintide. The comparison I want does not seem to exist anywhere in a form I can evaluate. I have read the arguments for each…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
liraglutide
liraglutide

A once-daily GLP-1 receptor agonist and the compound that established the class. Still relevant for its shorter half-life, its paediatric and…

235 questions
amylin
amylin

Amylin and its analogues, most prominently cagrilintide, as a satiety mechanism orthogonal to incretin signalling. Includes the pharmacology of…

237 questions
asked by void_volume 9.5k · 11 months ago
29 votes 5 answers17k views
Is there any published stability data for survodutide at 2–8 °C?

Concretely: survodutide · 2–8 °C. The claim is plausible, which is exactly why I want to check it. I am able to read a paper if someone points me at one. Has anyone…

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
storage
storage

Storage conditions and their evidence base: minus twenty degrees for powder, refrigerated for solution, protection from light, and what the…

701 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
survodutide
survodutide

A GLP-1 and glucagon receptor dual agonist with a substantial published MASH dataset. Use this tag for its hepatic endpoints, its dose ladder, and…

225 questions
asked by Dr_Otto_Lindqvist 72k · 11 months ago
29 votes0 answers13k views
Should I screen calcitonin before starting?

My laboratory results are from the same laboratory each time, drawn fasting, which I gather matters. I am trying to build something sustainable rather than something…

thyroid
thyroid

Thyroid questions: the rodent C-cell findings behind the labelled warning, human calcitonin data, TSH drift during weight loss, and the…

23 questions
bloodwork
bloodwork

Laboratory monitoring: which panels are worth ordering, sensible intervals, reference-range versus optimal-range arguments, and how to read a…

296 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
asked by retest_please 9.7k · 22 months ago
29 votes 5 answers13k views
What does REDEFINE-1 tell me about dizziness at the 2.4 mg dose?

The case in front of me: REDEFINE-1 · dizziness · 2.4 mg. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by samir_bennani 15k · 10 months ago
29 votes0 answers11k views
Why do two papers on STEP 4 report different headline figures?

The clinician who ordered the panel was not concerned; I would still like to understand it. This is one of those things that everyone repeats and nobody derives. This…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by ines_brandt 113k · 2.1 years ago
29 votes5 answers11k views
How comparable are ecnoglutide and mazdutide on the evidence available?

Setup, so nobody has to ask: ecnoglutide · mazdutide. I would like the axes of comparison first and the recommendation second. I have tried the first option and it…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
ecnoglutide
ecnoglutide

A long-acting GLP-1 receptor agonist with a cAMP-biased signalling profile. A niche tag, mostly used for mechanism questions about biased agonism…

223 questions
mazdutide
mazdutide

A GLP-1 and glucagon receptor dual agonist developed primarily in China, with a distinct dose range and a fast-moving publication record.…

237 questions
asked by tare_and_weigh 12k · 8 months ago
28 votes5 answers41k views
What did the placebo arm of STEP 8 report for vomiting?

What I am working with: STEP 8 · vomiting. I would like help reading this properly rather than being told what conclusion to reach. I have the full report including…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
vomiting
vomiting

Emesis as a reported adverse event: trial incidence, its relationship to dose escalation rate, dehydration risk, and when it stops being a…

57 questions
asked by threadlock7 19k · 18 months ago
28 votes 5 answers38k views
Is there any published stability data for a GLP-1 receptor agonist at minus 20 °C?

What I have: a GLP-1 receptor agonist · minus 20 °C. I am asking for verification rather than opinion, ideally with something I can read myself. It is possible the…

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
storage
storage

Storage conditions and their evidence base: minus twenty degrees for powder, refrigerated for solution, protection from light, and what the…

701 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
asked by assay_blank 45k · 2.3 years ago
28 votes 2 answers35k views
What did the placebo arm of STEP 1 report for headache?

The specifics, since they change the answer: STEP 1 · headache. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

472 questions
asked by leonid_marchuk 19k · 22 months ago
28 votes 5 answers29k views
What did the placebo arm of SURMOUNT-4 report for constipation?

For reference: SURMOUNT-4 · constipation. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
constipation
constipation

Slowed transit as a consequence of delayed gastric emptying and reduced intake: incidence figures, fibre and hydration evidence, and why it often…

55 questions
asked by label_claim 30k · 17 months ago
28 votes 5 answers28k views
Does the REDEFINE-1 population resemble anyone asking about cagrilintide here?

Conditions: REDEFINE-1 · cagrilintide. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single result,…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

472 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
amylin
amylin

Amylin and its analogues, most prominently cagrilintide, as a satiety mechanism orthogonal to incretin signalling. Includes the pharmacology of…

237 questions
asked by seven_day_half 31k · 15 months ago
28 votes 5 answers28k views
What did the placebo arm of STEP 8 report for constipation?

What I have: STEP 8 · constipation. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
constipation
constipation

Slowed transit as a consequence of delayed gastric emptying and reduced intake: incidence figures, fibre and hydration evidence, and why it often…

55 questions
asked by zeynep_arslan 16k · 21 months ago
28 votes0 answers28k views
Is there any published stability data for liraglutide at 40 °C?

The specifics, since they change the answer: liraglutide · 40 °C. I would like to know whether this claim survives contact with evidence. If the answer is "nobody has…

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
storage
storage

Storage conditions and their evidence base: minus twenty degrees for powder, refrigerated for solution, protection from light, and what the…

701 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
liraglutide
liraglutide

A once-daily GLP-1 receptor agonist and the compound that established the class. Still relevant for its shorter half-life, its paediatric and…

235 questions
asked by j_wierzbicki 69k · 22 months ago
28 votes5 answers25k views
How do I convert the SURMOUNT-4 hazard ratio into an absolute risk reduction?

I have three data points across nine months, which I hope is enough to see a trend. I can do the algebra. I am not confident about the conversion factors. If there is…

cardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

68 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
asked by elke_brunner 17k · 2.0 years ago
28 votes 5 answers24k views
What did the placebo arm of ATTAIN-1 report for reflux?

Concretely: ATTAIN-1 · reflux. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single result, which I…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

162 questions
asked by yuki_morishita 10k · 8 months ago
28 votes5 answers24k views
What does SOUL tell me about vomiting at the 14 mg dose?

Conditions: SOUL · vomiting · 14 mg. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single result,…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
vomiting
vomiting

Emesis as a reported adverse event: trial incidence, its relationship to dose escalation rate, dehydration risk, and when it stops being a…

57 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by nils_karlberg 9.4k · 13 months ago
28 votes 4 answers21k views
What does STEP 1 tell me about constipation at the 1 mg dose?

The specifics, since they change the answer: STEP 1 · constipation · 1 mg. I have the document in front of me and I can read the numbers. What I cannot do is…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
constipation
constipation

Slowed transit as a consequence of delayed gastric emptying and reduced intake: incidence figures, fibre and hydration evidence, and why it often…

55 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by mass_shift_18 9.7k · 12 months ago
28 votes 5 answers21k views
Does the PIONEER-1 population resemble anyone asking about oral semaglutide here?

Numbers first: PIONEER-1 · oral semaglutide. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

472 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
oral-glp1
oral-glp1

Oral routes for GLP-1 receptor agonism: peptide formulations rescued by absorption enhancers such as SNAC, and true small molecules that need no…

219 questions
asked by samir_bennani 15k · 22 months ago
28 votes 5 answers19k views
What does SOUL tell me about dizziness at the 7 mg dose?

Conditions: SOUL · dizziness · 7 mg. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the specifics…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by ayo_fadipe 9.4k · 16 months ago
28 votes 5 answers19k views
Is SELECT a fair comparison of semaglutide against its comparator arm?

For reference: SELECT · semaglutide. I am asking for verification rather than opinion, ideally with something I can read myself. It is possible the evidence exists…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
asked by eighty_six_hours 20k · 20 months ago
28 votes0 answers18k views
What does STEP 5 report at the 2.4 mg dose level?

The case in front of me: STEP 5 · 2.4 mg. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by wren_calloway 23k · 10 months ago